


Advance your antibody-drug conjugate pipeline with our experience and expertise

~200 ADCs are undergoing clinical trials

Antibody-drug conjugate (ADCs) trials are expanding

Over the past decade the number of new ADCs entering clinical trials each year has risen from a trickle to dozens per year, and will likely continue to increase as the effectiveness of currently-marketed ADCs is proven over time.




<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10794012/>

15 ADCs have received FDA approval

Approval rates have ramped up in recent years


With the increased number of ADC trials, the pace of approvals has accelerated, leading to the marketing of ADCs for a range of cancer indications ranging from hematological malignancies to solid tumors such as NSC lung cancer, breast cancer and bladder cancer.



\$12B ...and growing at 15%+ CAGR: global market size for ADCs

Rapidly growing ADC market size

ADCs are recognized as having relatively low systemic toxicity and for being effective, driving a rapid increase in market size, with the greatest revenue share percentage being in the North American market. While breast cancer represents nearly half of market revenue, hematological cancer ADCs are expected to grow strongly in the coming years.




marketsandmarkets.com/Market-Reports/antibody-drug-conjugates-market-122857391.html

59
trials

Fortrea
experience
with ADCs
2019-2023

Fortrea is a leader in the design and execution of ADC trials

Fortrea brings deep experience in ADCs, as part of our overall support for 1,365 oncology trials in the last five years. With experience in all major indications for ADCs, we deliver the trial design, regulatory, recruitment and trial execution insights you need.



Americas 39 APAC 35 EU 32 MEA 3 Other 2

3 Recent publications by Fortrea SMEs about our work in ADCs



Fortrea oncologists are thought-leader partners

Our oncologists have participated in over 35 peer-reviewed journal articles since 2020, including several focusing on ADCs for indications such as breast cancer and non-small-cell lung cancer. We are not just an ordinary CRO; our SMEs collaborate with industry and academic leaders to bring insights to the industry.



ADC pub list



Full oncology pub list

~60 Physicians in our oncology team, with deep experience in ADCs and hematologic and solid cancers



Get the insights your trial needs from our team of oncology experts

We bring you a team that is committed to navigating the complexities of oncology clinical research and maximizing the impact of your product to the current global therapeutic landscape. Our team of medical experts and consultants includes oncology physicians with an average of 23 years of clinical practice or clinical research experience across Europe, North America, Latin America and Asia Pacific.



Meet our oncology team

Choose Fortrea for your next ADC trial

Whether you are just beginning first in human studies, or scaling up for a global registrational study, our team of ~60 oncologists has the experience and global scale to accelerate your progress to the next milestone.

LEARN MORE at fortrea.com/oncology

